6533b85afe1ef96bd12b984a

RESEARCH PRODUCT

Unexpected Modulation of Recall B and T Cell Responses after Immunization with Rotavirus-like Particles in the Presence of LT-R192G

Didier PoncetFatou ThiamJohn D. ClementsCyrille Di MartinoClaire CachiaEvelyne KohliFabienne BonAnnie CharpilienneChristelle Basset

subject

T-LymphocytesHealth Toxicology and Mutagenesismedicine.medical_treatmentT cellBacterial ToxinsDose-Response Relationship Immunologiclcsh:Medicinechemical and pharmacologic phenomenaBiologyToxicologyArticleregulatory T cellsEnterotoxinsMiceInterleukin 21Immune systemB-1a lymphocyteAdjuvants ImmunologicAntigenmedicineAnimalsIL-2 receptorCD25B cellB-LymphocytesMice Inbred BALB CB lymphocytemucosal immunizationEscherichia coli Proteinslcsh:RRotavirus VaccinesVirionFOXP3LT-R192Ghemic and immune systemsrotavirusmedicine.anatomical_structureFoxp3ImmunologyFemaleImmunizationAdjuvant

description

LT-R192G, a mutant of the thermolabile enterotoxin of E. coli, is a potent adjuvant of immunization. Immune responses are generally analyzed at the end of protocols including at least 2 administrations, but rarely after a prime. To investigate this point, we compared B and T cell responses in mice after one and two intrarectal immunizations with 2/6 rotavirus-like particles (2/6-VLP) and LT-R192G. After a boost, we found, an unexpected lower B cell expansion measured by flow cytometry, despite a secondary antibody response. We then analyzed CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) and CD4(+)CD25(+)Foxp3(-) helper T cells after in vitro (re)stimulation of mesenteric lymph node cells with the antigen (2/6-VLP), the adjuvant (LT-R192G) or both. 2/6-VLP did not activate CD4(+)CD25(+)Foxp3(-) nor Foxp3(+) T cells from non-immunized and 2/6-VLP immunized mice, whereas they did activate both subsets from mice immunized with 2/6-VLP in the presence of adjuvant. LT-R192G dramatically decreased CD4(+)CD25(+)Foxp3(+) T cells from non-immunized and 2/6-VLP immunized mice but not from mice immunized with 2/6-VLP and adjuvant. Moreover, in this case, LT-R192G increased Foxp3 expression on CD4(+)CD25(+)Foxp3(+) cells, suggesting specific Treg activation during the recall. Finally, when both 2/6-VLP and LT-R192G were used for restimulation, LT-R192G clearly suppressed both 2/6-VLP-specific CD4(+)CD25(+)Foxp3(-) and Foxp3(+) T cells. All together, these results suggest that LT-R192G exerts different effects on CD4(+)CD25(+)Foxp3(+) T cells, depending on a first or a second contact. The unexpected immunomodulation observed during the recall should be considered in designing vaccination protocols.

https://doi.org/10.3390/toxins2082007